Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598766 (
leukemogenesis
)
4,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Both profound neutropenia and functional phagocyte disorders render patients susceptible to recurrent, unusual, and/or life-threatening infections. Many disorders also have nonhematologic manifestations and a substantial risk of
leukemogenesis
. Diagnosis relies on clinical suspicion and interrogation of the complete blood count with differential/bone marrow examination coupled with immunologic and genetic analyses. Treatment of the quantitative neutrophil disorders depends on
granulocyte colony-stimulating factor
, whereas management of functional phagocyte disease is reliant on antimicrobials and/or targeted therapies. Hematopoietic stem cell transplant remains the only curative option for most disorders but is not used on a routine basis.
...
PMID:Congenital Neutropenia and Rare Functional Phagocyte Disorders in Children. 3103 Aug 18
Severe congenital neutropenia (SCN) is characterized by a near absence of neutrophils, rendering individuals with this disorder vulnerable to recurrent life-threatening infections. The majority of SCN cases arise because of germline mutations in the gene elastase, neutrophil-expressed (
ELANE
) encoding the neutrophil granule serine protease neutrophil elastase. Treatment with a high dose of
granulocyte colony-stimulating factor
increases neutrophil production and reduces infection risk. How
ELANE
mutations produce SCN remains unknown. The currently proposed mechanism is that
ELANE
mutations promote protein misfolding, resulting in endoplasmic reticulum stress and activation of the unfolded protein response (UPR), triggering death of neutrophil precursors and resulting in neutropenia. Here we studied the
ELANE
mutation p.G185R, often associated with greater clinical severity (
e.g.
decreased responsiveness to
granulocyte colony-stimulating factor
and increased
leukemogenesis
). Using an inducible expression system, we observed that this
ELANE
mutation diminishes enzymatic activity and granulocytic differentiation without significantly affecting cell proliferation, cell death, or UPR induction in murine myeloblast 32D and human promyelocytic NB4 cells. Impaired differentiation was associated with decreased expression of genes encoding critical hematopoietic transcription factors (
Gfi1
,
Cebpd
,
Cebpe
, and
Spi1
), cell surface proteins (
Csf3r
and
Gr1
), and neutrophil granule proteins (
Mpo
and
Elane
). Together, these findings challenge the currently prevailing model that SCN results from mutant
ELANE
, which triggers endoplasmic reticulum stress, UPR, and apoptosis.
...
PMID:Inducible expression of a disease-associated
ELANE
mutation impairs granulocytic differentiation, without eliciting an unfolded protein response. 3229 10
Fusions of the Runt-related transcription factor 1 (RUNX1) with different partner genes have been associated with various hematological disorders. Interestingly, the C-terminally truncated form of RUNX1 and RUNX1 fusion proteins are similarly considered important contributors to
leukemogenesis
. Here, we describe a 59-year-old male patient who was initially diagnosed with acute myeloid leukemia, inv(16)(p13;q22)/CBFB-MYH11 (FAB classification M4Eo). He achieved complete remission and negative CBFB-MYH11 status with daunorubicin/cytarabine combination chemotherapy but relapsed 3 years later. Cytogenetic analysis of relapsed leukemia cells revealed CBFB-MYH11 negativity and complex chromosomal abnormalities without inv(16)(p13;q22). RNA-seq identified the glutamate receptor, ionotropic, kinase 2 (GRIK2) gene on 6q16 as a novel fusion partner for RUNX1 in this case. Specifically, the fusion of RUNX1 to the GRIK2 antisense strand (RUNX1-GRIK2as) generated multiple missplicing transcripts. Because extremely low levels of wild-type GRIK2 were detected in leukemia cells, RUNX1-GRIK2as was thought to drive the pathogenesis associated with the RUNX1-GRIK2 fusion. The truncated RUNX1 generated from RUNX1-GRIK2as induced the expression of the
granulocyte colony-stimulating factor
(
G-CSF
) receptor on 32D myeloid leukemia cells and enhanced proliferation in response to
G-CSF
. In summary, the RUNX1-GRIK2as fusion emphasizes the importance of aberrantly truncated RUNX1 in
leukemogenesis
.
...
PMID:Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating Factor. 3254 10
<< Previous
1
2
3
4